302 related articles for article (PubMed ID: 12907622)
1. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak AK; Robinson BW; Lake RA
Cancer Res; 2003 Aug; 63(15):4490-6. PubMed ID: 12907622
[TBL] [Abstract][Full Text] [Related]
2. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.
Broomfield S; Currie A; van der Most RG; Brown M; van Bruggen I; Robinson BW; Lake RA
Cancer Res; 2005 Sep; 65(17):7580-4. PubMed ID: 16140921
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.
McDonnell AM; Lesterhuis WJ; Khong A; Nowak AK; Lake RA; Currie AJ; Robinson BW
Eur J Immunol; 2015 Jan; 45(1):49-59. PubMed ID: 25316312
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.
Nowak AK; Robinson BW; Lake RA
Cancer Res; 2002 Apr; 62(8):2353-8. PubMed ID: 11956096
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
7. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
Fridlender ZG; Sun J; Singhal S; Kapoor V; Cheng G; Suzuki E; Albelda SM
Mol Ther; 2010 Nov; 18(11):1947-59. PubMed ID: 20683443
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
Lesterhuis WJ; Salmons J; Nowak AK; Rozali EN; Khong A; Dick IM; Harken JA; Robinson BW; Lake RA
PLoS One; 2013; 8(4):e61895. PubMed ID: 23626745
[TBL] [Abstract][Full Text] [Related]
10. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
11. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity.
Huffman AP; Lin JH; Kim SI; Byrne KT; Vonderheide RH
JCI Insight; 2020 May; 5(10):. PubMed ID: 32324594
[TBL] [Abstract][Full Text] [Related]
12. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM
Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
Nowak AK; Lake RA; Marzo AL; Scott B; Heath WR; Collins EJ; Frelinger JA; Robinson BW
J Immunol; 2003 May; 170(10):4905-13. PubMed ID: 12734333
[TBL] [Abstract][Full Text] [Related]
14. Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors.
Jang HY; Han BS; Kwon B; Sin JI
DNA Cell Biol; 2018 Oct; 37(10):850-860. PubMed ID: 30227079
[TBL] [Abstract][Full Text] [Related]
15. CCL2 blockade augments cancer immunotherapy.
Fridlender ZG; Buchlis G; Kapoor V; Cheng G; Sun J; Singhal S; Crisanti MC; Wang LC; Heitjan D; Snyder LA; Albelda SM
Cancer Res; 2010 Jan; 70(1):109-18. PubMed ID: 20028856
[TBL] [Abstract][Full Text] [Related]
16. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
Jackaman C; Lew AM; Zhan Y; Allan JE; Koloska B; Graham PT; Robinson BW; Nelson DJ
Int Immunol; 2008 Nov; 20(11):1467-79. PubMed ID: 18824504
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Du B; Wen X; Wang Y; Lin M; Lai J
Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
[TBL] [Abstract][Full Text] [Related]
19. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
20. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
